{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:37:41Z","timestamp":1780439861214,"version":"3.54.1"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00105-026-05683-5","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T07:18:56Z","timestamp":1777360736000},"page":"411-424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Biologikatherapie und Infektionen: Verstehen und Erkennen","Biologics and infections: understand and recognize"],"prefix":"10.1007","volume":"77","author":[{"given":"Galina","family":"Balakirski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Nenoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"issue":"7","key":"5683_CR1","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel\u00a0L, Bathon\u00a0JM, England\u00a0BR, St Clair\u00a0EW, Arayssi\u00a0T, Carandang\u00a0K, Deane\u00a0KD, Genovese\u00a0M, Huston\u00a0KK, Kerr\u00a0G, Kremer\u00a0J, Nakamura\u00a0MC, Russell\u00a0LA, Singh\u00a0JA, Smith\u00a0BJ, Sparks\u00a0JA, Venkatachalam\u00a0S, Weinblatt\u00a0ME, Al-Gibbawi\u00a0M, Baker\u00a0JF, Barbour\u00a0KE, Barton\u00a0JL, Cappelli\u00a0L, Chamseddine\u00a0F, George\u00a0M, Johnson\u00a0SR, Kahale\u00a0L, Karam\u00a0BS, Khamis\u00a0AM, Navarro-Mill\u00e1n\u00a0I, Mirza\u00a0R, Schwab\u00a0P, Singh\u00a0N, Turgunbaev\u00a0M, Turner\u00a0AS, Yaacoub\u00a0S, Akl\u00a0EA (2021) 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 73(7):1108\u20131123. https:\/\/doi.org\/10.1002\/art.41752","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"5683_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jaci.2023.01.002","volume":"151","author":"LB Bacharier","year":"2023","unstructured":"Bacharier\u00a0LB, Jackson\u00a0DJ (2023) Biologics in the treatment of asthma in children and adolescents. J\u00a0Allergy Clin Immunol 151(3):581\u2013589. https:\/\/doi.org\/10.1016\/j.jaci.2023.01.002","journal-title":"J Allergy Clin Immunol"},{"issue":"10516","key":"5683_CR3","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1016\/S0140-6736(25)01625-3","volume":"406","author":"E Israel","year":"2025","unstructured":"Israel\u00a0E, Wechsler\u00a0ME, Jackson\u00a0DJ, Moore\u00a0WC (2025) Anti-cytokine biologics for asthma in adults. Lancet 406(10516):2282\u20132294. https:\/\/doi.org\/10.1016\/S0140-6736(25)01625-3","journal-title":"Lancet"},{"issue":"2","key":"5683_CR4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/ddg.16001","volume":"24","author":"A Nast","year":"2026","unstructured":"Nast\u00a0A, Altenburg\u00a0A, Augustin\u00a0M, Bachmann\u00a0F, Boehncke\u00a0WH, Cornberg\u00a0M, Geerdes-Fenge\u00a0H, H\u00e4cker\u00a0B, H\u00e4rle\u00a0P, Klaus\u00a0J, K\u00f6hm\u00a0M, K\u00f6llner\u00a0A, Mrowietz\u00a0U, Ockenfels\u00a0HM, Pennitz\u00a0A, Philipp\u00a0S, Richter\u00a0T, Rosenbach\u00a0T, Schaberg\u00a0T, Schlaeger\u00a0M, Schmid-Ott\u00a0G, Sebastian\u00a0M, Th\u00f6lken\u00a0K, von Kiedrowski\u00a0R, Willuhn\u00a0U, Zeyen\u00a0C (2026) S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - part 2: Specific clinical and comorbid situations. J\u00a0Dtsch Dermatol Ges 24(2):270\u2013282. https:\/\/doi.org\/10.1111\/ddg.16001","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"5683_CR5","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/ddg.15412","volume":"22","author":"CC Zouboulis","year":"2024","unstructured":"Zouboulis\u00a0CC, Bechara\u00a0FG, Fritz\u00a0K, Goebeler\u00a0M, Hetzer\u00a0FH, Just\u00a0E, Kirsten\u00a0N, Kokolakis\u00a0G, Kurzen\u00a0H, Nikolakis\u00a0G, Pinter\u00a0A, Podda\u00a0M, Rosinski\u00a0K, Schneider-Burrus\u00a0S, Taube\u00a0KM, Volz\u00a0T, Winkler\u00a0T, Kristandt\u00a0A, Presser\u00a0D, Zouboulis\u00a0VA (2024) S2k guideline for the treatment of hidradenitis suppurativa \/ acne inversa - Short version. J\u00a0Dtsch Dermatol Ges 22(6):868\u2013889. https:\/\/doi.org\/10.1111\/ddg.15412","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"5683_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/ddg.15229","volume":"22","author":"T Werfel","year":"2024","unstructured":"Werfel\u00a0T, Heratizadeh\u00a0A, Aberer\u00a0W, Augustin\u00a0M, Biedermann\u00a0T, Bauer\u00a0A, F\u00f6lster-Holst\u00a0R, Kahle\u00a0J, Kinberger\u00a0M, Nemat\u00a0K, Neust\u00e4dter\u00a0I, Peters\u00a0E, von Kiedrowski\u00a0R, Schmid-Grendelmeier\u00a0P, Schmitt\u00a0J, Schwennesen\u00a0T, Simon\u00a0D, Spindler\u00a0T, Traidl-Hoffmann\u00a0C, Werner\u00a0RN, Wollenberg\u00a0A, Worm\u00a0M, Ott\u00a0H (2024) S3 guideline Atopic dermatitis: Part 2 - Systemic treatment. J\u00a0Dtsch Dermatol Ges 22(2):307\u2013320. https:\/\/doi.org\/10.1111\/ddg.15229","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"5683_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis\u00a0A, Kostopoulou\u00a0M, Andersen\u00a0J, Aringer\u00a0M, Arnaud\u00a0L, Bae\u00a0SC, Boletis\u00a0J, Bruce\u00a0IN, Cervera\u00a0R, Doria\u00a0A, D\u00f6rner\u00a0T, Furie\u00a0RA, Gladman\u00a0DD, Houssiau\u00a0FA, In\u00eas\u00a0LS, Jayne\u00a0D, Kouloumas\u00a0M, Kov\u00e1cs\u00a0L, Mok\u00a0CC, Morand\u00a0EF, Moroni\u00a0G, Mosca\u00a0M, Mucke\u00a0J, Mukhtyar\u00a0CB, Nagy\u00a0G, Navarra\u00a0S, Parodis\u00a0I, Pego-Reigosa\u00a0JM, Petri\u00a0M, Pons-Estel\u00a0BA, Schneider\u00a0M, Smolen\u00a0JS, Svenungsson\u00a0E, Tanaka\u00a0Y, Tektonidou\u00a0MG, Teng\u00a0YO, Tincani\u00a0A, Vital\u00a0EM, van Vollenhoven\u00a0RF, Wincup\u00a0C, Bertsias\u00a0G, Boumpas\u00a0DT (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83(1):15\u201329. https:\/\/doi.org\/10.1136\/ard-2023-224762","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"5683_CR8","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/ddg.14097_g","volume":"18","author":"E Schmidt","year":"2020","unstructured":"Schmidt\u00a0E, Sticherling\u00a0M, S\u00e1rdy\u00a0M, Eming\u00a0R, Goebeler\u00a0M, Hertl\u00a0M, Hofmann\u00a0SC, Hunzelmann\u00a0N, Kern\u00a0JS, Kramer\u00a0H, Nast\u00a0A, Orzechowski\u00a0HD, Pfeiffer\u00a0C, Schuster\u00a0V, Sitaru\u00a0C, Zidane\u00a0M, Zillikens\u00a0D, Worm\u00a0M (2020) S2k-Leitlinie zur Therapie des Pemphigus vulgaris\/foliaceus und des bull\u00f6sen Pemphigoids: 2019 Update. J\u00a0Dtsch Dermatol Ges 18(5):516\u2013527. https:\/\/doi.org\/10.1111\/ddg.14097_g","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"5683_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.idc.2020.02.006","volume":"34","author":"DY Ho","year":"2020","unstructured":"Ho\u00a0DY, Enriquez\u00a0K, Multani\u00a0A (2020) Herpesvirus Infections Potentiated by Biologics. Infect Dis Clin North Am 34(2):311\u2013339. https:\/\/doi.org\/10.1016\/j.idc.2020.02.006","journal-title":"Infect Dis Clin North Am"},{"issue":"2","key":"5683_CR10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.idc.2020.02.010","volume":"34","author":"MR Davis","year":"2020","unstructured":"Davis\u00a0MR, Thompson\u00a0GR 3rd, Patterson\u00a0TF (2020) Fungal Infections Potentiated by Biologics. Infect Dis Clin North Am 34(2):389\u2013411. https:\/\/doi.org\/10.1016\/j.idc.2020.02.010","journal-title":"Infect Dis Clin North Am"},{"issue":"3","key":"5683_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1699-0463.1995.tb01092.x","volume":"103","author":"F Belardelli","year":"1995","unstructured":"Belardelli\u00a0F (1995) Role of interferons and other cytokines in the regulation of the immune response. APMIS 103(3):161\u2013179. https:\/\/doi.org\/10.1111\/j.1699-0463.1995.tb01092.x","journal-title":"APMIS"},{"issue":"3","key":"5683_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012567","volume":"7","author":"Z Zhang","year":"2017","unstructured":"Zhang\u00a0Z, Fan\u00a0W, Yang\u00a0G, Xu\u00a0Z, Wang\u00a0J, Cheng\u00a0Q, Yu\u00a0M (2017) Risk of tuberculosis in patients treated with TNF\u2011\u03b1 antagonists: a\u00a0systematic review and meta-analysis of randomised controlled trials. BMJ Open 7(3):e012567. https:\/\/doi.org\/10.1136\/bmjopen-2016-012567","journal-title":"BMJ Open"},{"issue":"5","key":"5683_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.crohns.2010.05.001","volume":"4","author":"K Cheent","year":"2010","unstructured":"Cheent\u00a0K, Nolan\u00a0J, Shariq\u00a0S, Kiho\u00a0L, Pal\u00a0A, Arnold\u00a0J (2010) Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn\u2019s disease. J\u00a0Crohns Colitis 4(5):603\u2013605. https:\/\/doi.org\/10.1016\/j.crohns.2010.05.001","journal-title":"J Crohns Colitis"},{"issue":"4","key":"5683_CR14","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jaad.2011.04.030","volume":"65","author":"MM Heller","year":"2011","unstructured":"Heller\u00a0MM, Wu\u00a0JJ, Murase\u00a0JE (2011) Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab. J\u00a0Am Acad Dermatol 65(4):870. https:\/\/doi.org\/10.1016\/j.jaad.2011.04.030","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"5683_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jamadermatol.2020.3257","volume":"157","author":"BE Elewski","year":"2021","unstructured":"Elewski\u00a0BE, Baddley\u00a0JW, Deodhar\u00a0AA, Magrey\u00a0M, Rich\u00a0PA, Soriano\u00a0ER, Soung\u00a0J, Bao\u00a0W, Keininger\u00a0D, Marfo\u00a0K, Patekar\u00a0M, Sharma\u00a0A, Shete\u00a0A, Lebwohl\u00a0MG (2021) Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis. JAMA Dermatol 157(1):43\u201351. https:\/\/doi.org\/10.1001\/jamadermatol.2020.3257","journal-title":"JAMA Dermatol"},{"key":"5683_CR16","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v105.42081","volume":"105","author":"J Li","year":"2025","unstructured":"Li\u00a0J, Xiang\u00a0X, Wang\u00a0Z, Miao\u00a0C, Chen\u00a0Y, Xu\u00a0Z (2025) Safety of Interleukin Inhibitors in Psoriatic Patients with Latent Tuberculosis Infection Without Chemoprophylaxis: A Systematic Review. Acta Derm Venereol 105:adv42081. https:\/\/doi.org\/10.2340\/actadv.v105.42081","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"5683_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216234","volume":"14","author":"S Thee","year":"2019","unstructured":"Thee\u00a0S, Kr\u00fcger\u00a0R, von Bernuth\u00a0H, Meisel\u00a0C, K\u00f6lsch\u00a0U, Kirchberger\u00a0V, Feiterna-Sperling\u00a0C (2019) Screening and treatment for tuberculosis in a\u00a0cohort of unaccompanied minor refugees in Berlin, Germany. PLoS One 14(5):e0216234. https:\/\/doi.org\/10.1371\/journal.pone.0216234","journal-title":"PLoS One"},{"issue":"2","key":"5683_CR18","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/1756-185X.14034","volume":"24","author":"S Fidan","year":"2021","unstructured":"Fidan\u00a0S, Capk\u0131n\u00a0E, Ar\u0131ca\u00a0DA, Durak\u00a0S, Okatan\u00a0IE (2021) Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor\u2011\u03b1 therapy. Int J Rheum Dis 24(2):254\u2013259. https:\/\/doi.org\/10.1111\/1756-185X.14034","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"5683_CR19","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s40261-022-01163-5","volume":"42","author":"M Megna","year":"2022","unstructured":"Megna\u00a0M, Patruno\u00a0C, Bongiorno\u00a0MR, Gambardella\u00a0A, Guarneri\u00a0C, Romita\u00a0P, Raimondo\u00a0A, Loconsole\u00a0F, Fabbrocini\u00a0G (2022) Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection. Clin Drug Investig 42(6):525\u2013531. https:\/\/doi.org\/10.1007\/s40261-022-01163-5","journal-title":"Clin Drug Investig"},{"issue":"6","key":"5683_CR20","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40257-019-00457-3","volume":"20","author":"S Piaserico","year":"2019","unstructured":"Piaserico\u00a0S, Messina\u00a0F, Russo\u00a0FP (2019) Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. Am J Clin Dermatol 20(6):829\u2013845. https:\/\/doi.org\/10.1007\/s40257-019-00457-3","journal-title":"Am J Clin Dermatol"},{"issue":"14","key":"5683_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000675","volume":"94","author":"H Bauer","year":"2015","unstructured":"Bauer\u00a0H, Luxembourger\u00a0C, Gottenberg\u00a0JE, Fournier\u00a0S, Abravanel\u00a0F, Cantagrel\u00a0A, Chatelus\u00a0E, Claudepierre\u00a0P, Hudry\u00a0C, Izopet\u00a0J, Fabre\u00a0S, Lefevre\u00a0G, Marguerie\u00a0L, Martin\u00a0A, Messer\u00a0L, Molto\u00a0A, Pallot-Prades\u00a0B, Pers\u00a0YM, Roque-Afonso\u00a0AM, Roux\u00a0C, Sordet\u00a0C, Soubrier\u00a0M, Veissier\u00a0C, Wendling\u00a0D, P\u00e9ron\u00a0JM, Sibilia\u00a0J, Club Rhumatismes et Inflammation, a section of the French Society of Rheumatology (2015) Outcome of hepatitis E virus infection in patients with inflammatory arthritides treated with immunosuppressants: a French retrospective multicenter study. Medicine (Baltimore) 94(14):e675. https:\/\/doi.org\/10.1097\/MD.0000000000000675","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"5683_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jbspin.2016.09.017","volume":"84","author":"P Behrendt","year":"2017","unstructured":"Behrendt\u00a0P, L\u00fcth\u00a0S, Dammermann\u00a0W, Drave\u00a0S, Brown\u00a0RJ, Todt\u00a0D, Schnoor\u00a0U, Steinmann\u00a0E, Wedemeyer\u00a0H, Pischke\u00a0S, Iking-Konert\u00a0C (2017) Exacerbation of hepatitis\u00a0E virus infection during anti-TNF\u03b1 treatment. Joint Bone Spine 84(2):217\u2013219. https:\/\/doi.org\/10.1016\/j.jbspin.2016.09.017","journal-title":"Joint Bone Spine"},{"issue":"5","key":"5683_CR23","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.jaad.2015.11.043","volume":"74","author":"SM Gallitano","year":"2016","unstructured":"Gallitano\u00a0SM, McDermott\u00a0L, Brar\u00a0K, Lowenstein\u00a0E (2016) Use of tumor necrosis factor (TNF) inhibitors in patients with HIV\/AIDS. J\u00a0Am Acad Dermatol 74(5):974\u2013980. https:\/\/doi.org\/10.1016\/j.jaad.2015.11.043","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"5683_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03395-1","volume":"317","author":"SV Shimon","year":"2024","unstructured":"Shimon\u00a0SV, Romanelli\u00a0P (2024) Systematic review of biologic use for psoriasis in HIV-positive individuals from 2018 to 2024. Arch Dermatol Res 317(1):14. https:\/\/doi.org\/10.1007\/s00403-024-03395-1","journal-title":"Arch Dermatol Res"},{"key":"5683_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100266","volume":"13","author":"L Davidson","year":"2021","unstructured":"Davidson\u00a0L, van den Reek\u00a0JMPA, Bruno\u00a0M, van Hunsel\u00a0F, Herings\u00a0RMC, Matzaraki\u00a0V, Boahen\u00a0CK, Kumar\u00a0V, Groenewoud\u00a0HMM, van de Veerdonk\u00a0FL, Netea\u00a0MG, de Jong\u00a0EMGJ, Kullberg\u00a0BJ (2021) Risk of candidiasis associated with interleukin-17\u00a0inhibitors: A\u00a0real-world observational study of multiple independent sources. Lancet Reg Health Eur 13:100266. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100266","journal-title":"Lancet Reg Health Eur"},{"issue":"10273","key":"5683_CR26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich\u00a0K, Papp\u00a0KA, Blauvelt\u00a0A, Langley\u00a0RG, Armstrong\u00a0A, Warren\u00a0RB, Gordon\u00a0KB, Merola\u00a0JF, Okubo\u00a0Y, Madden\u00a0C, Wang\u00a0M, Cioffi\u00a0C, Vanvoorden\u00a0V, Lebwohl\u00a0M (2021) Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet 397(10273):487\u2013498. https:\/\/doi.org\/10.1016\/S0140-6736(21)00125-2","journal-title":"Lancet"},{"issue":"10273","key":"5683_CR27","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","volume":"397","author":"KB Gordon","year":"2021","unstructured":"Gordon\u00a0KB, Foley\u00a0P, Krueger\u00a0JG, Pinter\u00a0A, Reich\u00a0K, Vender\u00a0R, Vanvoorden\u00a0V, Madden\u00a0C, White\u00a0K, Cioffi\u00a0C, Blauvelt\u00a0A (2021) Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet 397(10273):475\u2013486. https:\/\/doi.org\/10.1016\/S0140-6736(21)00126-4","journal-title":"Lancet"},{"issue":"10443","key":"5683_CR28","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","volume":"403","author":"AB Kimball","year":"2024","unstructured":"Kimball\u00a0AB, Jemec\u00a0GBE, Sayed\u00a0CJ, Kirby\u00a0JS, Prens\u00a0E, Ingram\u00a0JR, Garg\u00a0A, Gottlieb\u00a0AB, Szepietowski\u00a0JC, Bechara\u00a0FG, Giamarellos-Bourboulis\u00a0EJ, Fujita\u00a0H, Rolleri\u00a0R, Joshi\u00a0P, Dokhe\u00a0P, Muller\u00a0E, Peterson\u00a0L, Madden\u00a0C, Bari\u00a0M, Zouboulis\u00a0CC (2024) Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet 403(10443):2504\u20132519. https:\/\/doi.org\/10.1016\/S0140-6736(24)00101-6","journal-title":"Lancet"},{"issue":"2","key":"5683_CR29","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjd.14493","volume":"175","author":"KA Papp","year":"2016","unstructured":"Papp\u00a0KA, Reich\u00a0K, Paul\u00a0C, Blauvelt\u00a0A, Baran\u00a0W, Bolduc\u00a0C, Toth\u00a0D, Langley\u00a0RG, Cather\u00a0J, Gottlieb\u00a0AB, Tha\u00e7i\u00a0D, Krueger\u00a0JG, Russell\u00a0CB, Milmont\u00a0CE, Li\u00a0J, Klekotka\u00a0PA, Kricorian\u00a0G, Nirula\u00a0A (2016) A\u00a0prospective phase\u00a0III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 175(2):273\u2013286. https:\/\/doi.org\/10.1111\/bjd.14493","journal-title":"Br J Dermatol"},{"issue":"4","key":"5683_CR30","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon\u00a0KB, Blauvelt\u00a0A, Papp\u00a0KA, Langley\u00a0RG, Luger\u00a0T, Ohtsuki\u00a0M, Reich\u00a0K, Amato\u00a0D, Ball\u00a0SG, Braun\u00a0DK, Cameron\u00a0GS, Erickson\u00a0J, Konrad\u00a0RJ, Muram\u00a0TM, Nickoloff\u00a0BJ, Osuntokun\u00a0OO, Secrest\u00a0RJ, Zhao\u00a0F, Mallbris\u00a0L, Leonardi\u00a0CL, UNCOVER\u20111 Study Group, UNCOVER\u20112 Study Group, UNCOVER\u20113 Study Group (2016) Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N\u00a0Engl J Med 375(4):345\u2013356. https:\/\/doi.org\/10.1056\/NEJMoa1512711","journal-title":"N Engl J Med"},{"issue":"4","key":"5683_CR31","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley\u00a0RG, Elewski\u00a0BE, Lebwohl\u00a0M, Reich\u00a0K, Griffiths\u00a0CE, Papp\u00a0K, Puig\u00a0L, Nakagawa\u00a0H, Spelman\u00a0L, Sigurgeirsson\u00a0B, Rivas\u00a0E, Tsai\u00a0TF, Wasel\u00a0N, Tyring\u00a0S, Salko\u00a0T, Hampele\u00a0I, Notter\u00a0M, Karpov\u00a0A, Helou\u00a0S, Papavassilis\u00a0C, ERASURE Study Group, FIXTURE Study Group (2014) Secukinumab in plaque psoriasis--results of two phase 3 trials. N\u00a0Engl J Med 371(4):326\u2013338. https:\/\/doi.org\/10.1056\/NEJMoa1314258","journal-title":"N Engl J Med"},{"issue":"10201","key":"5683_CR32","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich\u00a0K, Armstrong\u00a0AW, Langley\u00a0RG, Flavin\u00a0S, Randazzo\u00a0B, Li\u00a0S, Hsu\u00a0MC, Branigan\u00a0P, Blauvelt\u00a0A (2019) Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet 394(10201):831\u2013839. https:\/\/doi.org\/10.1016\/S0140-6736(19)31773-8","journal-title":"Lancet"},{"issue":"10378","key":"5683_CR33","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball\u00a0AB, Jemec\u00a0GBE, Alavi\u00a0A, Reguiai\u00a0Z, Gottlieb\u00a0AB, Bechara\u00a0FG, Paul\u00a0C, Giamarellos Bourboulis\u00a0EJ, Villani\u00a0AP, Schwinn\u00a0A, Ru\u00ebff\u00a0F, Pillay Ramaya\u00a0L, Reich\u00a0A, Lobo\u00a0I, Sinclair\u00a0R, Passeron\u00a0T, Martorell\u00a0A, Mendes-Bastos\u00a0P, Kokolakis\u00a0G, Becherel\u00a0PA, Wozniak\u00a0MB, Martinez\u00a0AL, Wei\u00a0X, Uhlmann\u00a0L, Passera\u00a0A, Keefe\u00a0D, Martin\u00a0R, Field\u00a0C, Chen\u00a0L, Vandemeulebroecke\u00a0M, Ravichandran\u00a0S, Muscianisi\u00a0E (2023) Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week\u00a016 and week\u00a052 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase\u00a03\u00a0trials. Lancet 401(10378):747\u2013761. https:\/\/doi.org\/10.1016\/S0140-6736(23)00022-3","journal-title":"Lancet"},{"issue":"10","key":"5683_CR34","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s13555-023-01002-1","volume":"13","author":"AD Burden","year":"2023","unstructured":"Burden\u00a0AD, Bissonnette\u00a0R, Navarini\u00a0AA, Murakami\u00a0M, Morita\u00a0A, Haeufel\u00a0T, Ye\u00a0B, Baehner\u00a0F, Terui\u00a0T (2023) Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study. Dermatol Ther (Heidelb) 13(10):2279\u20132297. https:\/\/doi.org\/10.1007\/s13555-023-01002-1","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"5683_CR35","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s13555-024-01203-2","volume":"14","author":"M Mansilla-Polo","year":"2024","unstructured":"Mansilla-Polo\u00a0M, Morgado-Carrasco\u00a0D (2024) Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review. Dermatol Ther (Heidelb) 14(8):1983\u20132038. https:\/\/doi.org\/10.1007\/s13555-024-01203-2","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"12","key":"5683_CR36","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1111\/jdv.20724","volume":"39","author":"K Kridin","year":"2025","unstructured":"Kridin\u00a0K, Abdelghaffar\u00a0M, Bieber\u00a0K, Thaci\u00a0D, Ludwig\u00a0RJ (2025) The real-world, long-term risk of infections associated with dupilumab in atopic dermatitis: A\u00a0global cohort study. J\u00a0Eur Acad Dermatol Venereol 39(12):2069\u20132078. https:\/\/doi.org\/10.1111\/jdv.20724","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"5683_CR37","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjd.21867","volume":"187","author":"EL Simpson","year":"2022","unstructured":"Simpson\u00a0EL, Merola\u00a0JF, Silverberg\u00a0JI, Reich\u00a0K, Warren\u00a0RB, Staumont-Sall\u00e9\u00a0D, Girolomoni\u00a0G, Papp\u00a0K, de Bruin-Weller\u00a0M, Thyssen\u00a0JP, Zachariae\u00a0R, Olsen\u00a0CK, Wollenberg\u00a0A (2022) Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. Br J Dermatol 187(6):888\u2013899. https:\/\/doi.org\/10.1111\/bjd.21867","journal-title":"Br J Dermatol"},{"key":"5683_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70080","author":"M Augustin","year":"2025","unstructured":"Augustin\u00a0M, Tauber\u00a0M, Sidbury\u00a0R, Silverberg\u00a0JI, Papp\u00a0KA, Tha\u00e7i\u00a0D, De Bruin-Weller\u00a0MS, Reich\u00a0A, Peris\u00a0K, Barber\u00a0K, Galus\u00a0R, Kaszuba\u00a0A, Zirwas\u00a0M, Nahm\u00a0WK, Trullenque\u00a0G, Maintz\u00a0L, Alpizar\u00a0S, Son\u00a0SW, Laquer\u00a0V, Gold\u00a0LS, Cheong\u00a0SY, Ryzhkova\u00a0A, Drahos\u00a0A, Ulianov\u00a0L, Piketty\u00a0C (2025) Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study. J\u00a0Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.70080","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"5683_CR39","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/jdv.18922","volume":"37","author":"DN Adam","year":"2023","unstructured":"Adam\u00a0DN, Gooderham\u00a0MJ, Beecker\u00a0JR, Hong\u00a0CH, Jack\u00a0CS, Jain\u00a0V, Lansang\u00a0P, Lynde\u00a0CW, Papp\u00a0KA, Prajapati\u00a0VH, Turchin\u00a0I, Yeung\u00a0J (2023) Expert consensus on the systemic treatment of atopic dermatitis in special populations. J\u00a0Eur Acad Dermatol Venereol 37(6):1135\u20131148. https:\/\/doi.org\/10.1111\/jdv.18922","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"24","key":"5683_CR40","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson\u00a0EL, Bieber\u00a0T, Guttman-Yassky\u00a0E, Beck\u00a0LA, Blauvelt\u00a0A, Cork\u00a0MJ, Silverberg\u00a0JI, Deleuran\u00a0M, Kataoka\u00a0Y, Lacour\u00a0JP, Kingo\u00a0K, Worm\u00a0M, Poulin\u00a0Y, Wollenberg\u00a0A, Soo\u00a0Y, Graham\u00a0NM, Pirozzi\u00a0G, Akinlade\u00a0B, Staudinger\u00a0H, Mastey\u00a0V, Eckert\u00a0L, Gadkari\u00a0A, Stahl\u00a0N, Yancopoulos\u00a0GD, Ardeleanu\u00a0M, SOLO 1 and SOLO 2 Investigators (2016) Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N\u00a0Engl J Med 375(24):2335\u20132348. https:\/\/doi.org\/10.1056\/NEJMoa1610020","journal-title":"N Engl J Med"},{"issue":"5","key":"5683_CR41","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1093\/bjd\/ljaf285","volume":"193","author":"RB Warren","year":"2025","unstructured":"Warren\u00a0RB, de Bruin-Weller\u00a0M, Tsianakas\u00a0A, Khemis\u00a0A, Szepietowski\u00a0JC, Hong\u00a0HC, Mihaylov\u00a0Y, Falqu\u00e9s\u00a0M, Agell\u00a0H, Massana\u00a0E, Gil\u00a0EG, Coll\u00a0R, Weidinger\u00a0S (2025) Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin\u00a0A: a\u00a0placebo-controlled, randomized phase\u00a0IIIb clinical study (ADvantage). Br J Dermatol 193(5):876\u2013888. https:\/\/doi.org\/10.1093\/bjd\/ljaf285","journal-title":"Br J Dermatol"},{"issue":"3","key":"5683_CR42","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg\u00a0A, Blauvelt\u00a0A, Guttman-Yassky\u00a0E, Worm\u00a0M, Lynde\u00a0C, Lacour\u00a0JP, Spelman\u00a0L, Katoh\u00a0N, Saeki\u00a0H, Poulin\u00a0Y, Lesiak\u00a0A, Kircik\u00a0L, Cho\u00a0SH, Herranz\u00a0P, Cork\u00a0MJ, Peris\u00a0K, Steffensen\u00a0LA, Bang\u00a0B, Kuznetsova\u00a0A, Jensen\u00a0TN, \u00d8sterdal\u00a0ML, Simpson\u00a0EL, ECZTRA 1 and ECZTRA 2 study investigators (2021) Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 184(3):437\u2013449. https:\/\/doi.org\/10.1111\/bjd.19574","journal-title":"Br J Dermatol"},{"issue":"1","key":"5683_CR43","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jaad.2017.09.052","volume":"78","author":"P Fleming","year":"2018","unstructured":"Fleming\u00a0P, Drucker\u00a0AM (2018) Risk of infection in patients with atopic dermatitis treated with dupilumab: A\u00a0meta-analysis of randomized controlled trials. J\u00a0Am Acad Dermatol 78(1):62\u201369.e1. https:\/\/doi.org\/10.1016\/j.jaad.2017.09.052","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"5683_CR44","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","volume":"388","author":"JI Silverberg","year":"2023","unstructured":"Silverberg\u00a0JI, Guttman-Yassky\u00a0E, Tha\u00e7i\u00a0D, Irvine\u00a0AD, Stein Gold\u00a0L, Blauvelt\u00a0A, Simpson\u00a0EL, Chu\u00a0CY, Liu\u00a0Z, Gontijo Lima\u00a0R, Pillai\u00a0SG, Seneschal\u00a0J, ADvocate1 and ADvocate2 Investigators (2023) Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. N\u00a0Engl J Med 388(12):1080\u20131091. https:\/\/doi.org\/10.1056\/NEJMoa2206714","journal-title":"N Engl J Med"},{"issue":"1","key":"5683_CR45","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jid.2019.05.024","volume":"140","author":"C Callewaert","year":"2020","unstructured":"Callewaert\u00a0C, Nakatsuji\u00a0T, Knight\u00a0R, Kosciolek\u00a0T, Vrbanac\u00a0A, Kotol\u00a0P, Ardeleanu\u00a0M, Hultsch\u00a0T, Guttman-Yassky\u00a0E, Bissonnette\u00a0R, Silverberg\u00a0JI, Krueger\u00a0J, Menter\u00a0A, Graham\u00a0NMH, Pirozzi\u00a0G, Hamilton\u00a0JD, Gallo\u00a0RL (2020) IL-4R\u03b1 Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis. J\u00a0Invest Dermatol 140(1):191\u2013202.e7. https:\/\/doi.org\/10.1016\/j.jid.2019.05.024","journal-title":"J Invest Dermatol"},{"issue":"5","key":"5683_CR46","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jaci.2023.05.026","volume":"152","author":"EL Simpson","year":"2023","unstructured":"Simpson\u00a0EL, Schlievert\u00a0PM, Yoshida\u00a0T, Lussier\u00a0S, Boguniewicz\u00a0M, Hata\u00a0T, Fuxench\u00a0Z, De Benedetto\u00a0A, Ong\u00a0PY, Ko\u00a0J, Calatroni\u00a0A, Rudman Spergel\u00a0AK, Plaut\u00a0M, Quataert\u00a0SA, Kilgore\u00a0SH, Peterson\u00a0L, Gill\u00a0AL, David\u00a0G, Mosmann\u00a0T, Gill\u00a0SR, Leung\u00a0DYM, Beck\u00a0LA (2023) Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment. J\u00a0Allergy Clin Immunol 152(5):1179\u20131195. https:\/\/doi.org\/10.1016\/j.jaci.2023.05.026","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"5683_CR47","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jaad.2022.11.047","volume":"88","author":"LA Beck","year":"2023","unstructured":"Beck\u00a0LA, Bieber\u00a0T, Weidinger\u00a0S, Tauber\u00a0M, Saeki\u00a0H, Irvine\u00a0AD, Eichenfield\u00a0LF, Werfel\u00a0T, Arlert\u00a0P, Jiang\u00a0L, R\u00f8pke\u00a0M, Paller\u00a0AS (2023) Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA\u00a01, a\u00a0randomized controlled trial. J\u00a0Am Acad Dermatol 88(4):816\u2013823. https:\/\/doi.org\/10.1016\/j.jaad.2022.11.047","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"5683_CR48","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/ajd.14589","volume":"66","author":"ML Kelly","year":"2025","unstructured":"Kelly\u00a0ML, Miller\u00a0RM (2025) Case Series: Scabies Complicating Dupilumab Therapy for Atopic Dermatitis. Australas J Dermatol 66(7):422\u2013424. https:\/\/doi.org\/10.1111\/ajd.14589","journal-title":"Australas J Dermatol"},{"issue":"5","key":"5683_CR49","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1097\/DER.0000000000000926","volume":"33","author":"L Rodriguez-Lago","year":"2022","unstructured":"Rodriguez-Lago\u00a0L, Borrego\u00a0L (2022) Norwegian Scabies in an Atopic Patient Under Dupilumab Treatment. Dermatitis 33(5):e54\u2013e55. https:\/\/doi.org\/10.1097\/DER.0000000000000926","journal-title":"Dermatitis"},{"issue":"1","key":"5683_CR50","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00105-021-04895-1","volume":"73","author":"M Augustin","year":"2022","unstructured":"Augustin\u00a0M, Garbe\u00a0C, Girbig\u00a0G, Str\u00f6mer\u00a0K, Kirsten\u00a0N (2022) Epidemiologie der Skabies in Deutschland: Multi-Source-Analyse von Prim\u00e4r- und Sekund\u00e4rdaten [Epidemiology of scabies in Germany: multisource analysis of primary and secondary data]. Hautarzt 73(1):61\u201366. https:\/\/doi.org\/10.1007\/s00105-021-04895-1","journal-title":"Hautarzt"},{"issue":"3","key":"5683_CR51","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3390\/ph15030335","volume":"15","author":"P Pandey","year":"2022","unstructured":"Pandey\u00a0P, Khan\u00a0F, Qari\u00a0HA, Upadhyay\u00a0TK, Alkhateeb\u00a0AF, Oves\u00a0M (2022) Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD\u20111, PD-L1 and CTLA\u20114. Pharmaceuticals (Basel) 15(3):335\u2013335. https:\/\/doi.org\/10.3390\/ph15030335","journal-title":"Pharmaceuticals (Basel)"},{"issue":"Suppl 2(Suppl 2","key":"5683_CR52","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1016\/j.cmi.2018.01.030","volume":"24","author":"G Redelman-Sidi","year":"2018","unstructured":"Redelman-Sidi\u00a0G, Michielin\u00a0O, Cervera\u00a0C, Ribi\u00a0C, Aguado\u00a0JM, Fern\u00e1ndez-Ruiz\u00a0M, Manuel\u00a0O, ESCMID Study Group for Infections in Compromised Hosts (ESGICH) (2018) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). Clin Microbiol Infect 24(Suppl 2(Suppl 2)):S95\u2013S107. https:\/\/doi.org\/10.1016\/j.cmi.2018.01.030","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"5683_CR53","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/j.1349-7006.2006.00307.x","volume":"97","author":"T Ishida","year":"2006","unstructured":"Ishida\u00a0T, Ueda\u00a0R (2006) CCR4 as a\u00a0novel molecular target for immunotherapy of cancer. Cancer Sci 97(11):1139\u20131146. https:\/\/doi.org\/10.1111\/j.1349-7006.2006.00307.x","journal-title":"Cancer Sci"},{"key":"5683_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100601","volume":"28","author":"S Wang","year":"2020","unstructured":"Wang\u00a0S, Jayarangaiah\u00a0A, Malone\u00a0M, Elrafei\u00a0T, Steinberg\u00a0L, Kumar\u00a0A (2020) Risk of hepatitis B reactivation and cytomegalovirus related infections with Mogamulizumab: A retrospective study of international pharmacovigilance database. EClinicalMedicine 28:100601. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100601","journal-title":"EClinicalMedicine"},{"key":"5683_CR55","unstructured":"(2025) Fachinformation Poteligeo 4\u202fmg\/ml. https:\/\/www.fachinfo.de\/fi\/pdf\/022928. Accessed 3.1.2026"},{"issue":"9","key":"5683_CR56","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","volume":"19","author":"YH Kim","year":"2018","unstructured":"Kim\u00a0YH, Bagot\u00a0M, Pinter-Brown\u00a0L, Rook\u00a0AH, Porcu\u00a0P, Horwitz\u00a0SM, Whittaker\u00a0S, Tokura\u00a0Y, Vermeer\u00a0M, Zinzani\u00a0PL, Sokol\u00a0L, Morris\u00a0S, Kim\u00a0EJ, Ortiz-Romero\u00a0PL, Eradat\u00a0H, Scarisbrick\u00a0J, Tsianakas\u00a0A, Elmets\u00a0C, Dalle\u00a0S, Fisher\u00a0DC, Halwani\u00a0A, Poligone\u00a0B, Greer\u00a0J, Fierro\u00a0MT, Khot\u00a0A, Moskowitz\u00a0AJ, Musiek\u00a0A, Shustov\u00a0A, Pro\u00a0B, Geskin\u00a0LJ, Dwyer\u00a0K, Moriya\u00a0J, Leoni\u00a0M, Humphrey\u00a0JS, Hudgens\u00a0S, Grebennik\u00a0DO, Tobinai\u00a0K, Duvic\u00a0M, MAVORIC Investigators (2018) Mogamulizumab versus vorinostat in previously treated cutaneous T\u2011cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 19(9):1192\u20131204. https:\/\/doi.org\/10.1016\/S1470-2045(18)30379-6","journal-title":"Lancet Oncol"},{"issue":"4","key":"5683_CR57","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41375-019-0388-x","volume":"33","author":"G Maschmeyer","year":"2019","unstructured":"Maschmeyer\u00a0G, De Greef\u00a0J, Mellinghoff\u00a0SC, Nosari\u00a0A, Thiebaut-Bertrand\u00a0A, Bergeron\u00a0A, Franquet\u00a0T, Blijlevens\u00a0NMA, Maertens\u00a0JA, European Conference on Infections in Leukemia (ECIL) (2019) Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A\u00a0position paper by the European Conference on Infections in Leukemia (ECIL). Leukemia 33(4):844\u2013862. https:\/\/doi.org\/10.1038\/s41375-019-0388-x","journal-title":"Leukemia"},{"issue":"2","key":"5683_CR58","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx091","volume":"4","author":"JJ Tudesq","year":"2017","unstructured":"Tudesq\u00a0JJ, Vincent\u00a0L, Lebrun\u00a0J, Hicheri\u00a0Y, Gabellier\u00a0L, Busetto\u00a0T, Merle\u00a0C, Fegueux\u00a0N, Ceballos\u00a0P, Quittet\u00a0P, Navarro\u00a0R, Hillaire-Buys\u00a0D, Cartron\u00a0G (2017) Cytomegalovirus Infection With Retinitis After Brentuximab Vedotin Treatment for CD30+ Lymphoma. Open Forum Infect Dis 4(2):ofx091. https:\/\/doi.org\/10.1093\/ofid\/ofx091","journal-title":"Open Forum Infect Dis"},{"key":"5683_CR59","unstructured":"(2025) Fachinformation ADCETRIS 50\u202fmg, Stand Juni 2025. https:\/\/www.fachinfo.de\/fi\/detail\/014234\/adcetris-r. Accessed 10.1.2026"},{"issue":"8","key":"5683_CR60","doi-asserted-by":"publisher","first-page":"e624","DOI":"10.1016\/S2352-3026(23)00157-6","volume":"10","author":"PG Rubinstein","year":"2023","unstructured":"Rubinstein\u00a0PG, Moore\u00a0PC, Bimali\u00a0M, Lee\u00a0JY, Rudek\u00a0MA, Chadburn\u00a0A, Ratner\u00a0L, Henry\u00a0DH, Cesarman\u00a0E, DeMarco\u00a0CE, Costagliola\u00a0D, Taoufik\u00a0Y, Ramos\u00a0JC, Sharon\u00a0E, Reid\u00a0EG, Ambinder\u00a0RF, Mitsuyasu\u00a0R, Mounier\u00a0N, Besson\u00a0C, Noy\u00a0A, AIDS Malignancy Consortium, Lymphoma Study Association (2023) Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1\/2 trial. Lancet Haematol 10(8):e624\u2013e632. https:\/\/doi.org\/10.1016\/S2352-3026(23)00157-6","journal-title":"Lancet Haematol"},{"key":"5683_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.980079","volume":"13","author":"KA Kirou","year":"2022","unstructured":"Kirou\u00a0KA, Dall Era\u00a0M, Aranow\u00a0C, Anders\u00a0HJ (2022) Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. Front Immunol 13:980079. https:\/\/doi.org\/10.3389\/fimmu.2022.980079","journal-title":"Front Immunol"},{"key":"5683_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.999704","volume":"13","author":"S Steiger","year":"2022","unstructured":"Steiger\u00a0S, Ehreiser\u00a0L, Anders\u00a0J, Anders\u00a0HJ (2022) Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials. Front Immunol 13:999704. https:\/\/doi.org\/10.3389\/fimmu.2022.999704","journal-title":"Front Immunol"},{"issue":"2","key":"5683_CR63","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/art.42392","volume":"75","author":"KC Kalunian","year":"2023","unstructured":"Kalunian\u00a0KC, Furie\u00a0R, Morand\u00a0EF, Bruce\u00a0IN, Manzi\u00a0S, Tanaka\u00a0Y, Winthrop\u00a0K, Hupka\u00a0I, Zhang\u00a0LJ, Werther\u00a0S, Abreu\u00a0G, Hultquist\u00a0M, Tummala\u00a0R, Lindholm\u00a0C, Al-Mossawi\u00a0H (2023) A\u00a0Randomized, Placebo-Controlled Phase\u00a0III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. Arthritis Rheumatol 75(2):253\u2013265. https:\/\/doi.org\/10.1002\/art.42392","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"5683_CR64","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1111\/ddg.15790","volume":"23","author":"S Chambers","year":"2025","unstructured":"Chambers\u00a0S, Gomes\u00a0LLA, Yang\u00a0X, On\u00a0A, Ali\u00a0H, Khosravi-Hafshejani\u00a0T, DeQuattro\u00a0K, Thomas\u00a0P, Werth\u00a0VP (2025) Atypical infections during combination therapy with anifrolumab and other immunosuppressives in patients with lupus erythematosus: A\u00a0case series. J\u00a0Dtsch Dermatol Ges 23(9):1164\u20131167. https:\/\/doi.org\/10.1111\/ddg.15790","journal-title":"J Dtsch Dermatol Ges"},{"issue":"14","key":"5683_CR65","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2022112907","volume":"42","author":"L Dalskov","year":"2023","unstructured":"Dalskov\u00a0L, Gad\u00a0HH, Hartmann\u00a0R (2023) Viral recognition and the antiviral interferon response. EMBO\u00a0J 42(14):e112907. https:\/\/doi.org\/10.15252\/embj.2022112907","journal-title":"EMBO J"},{"issue":"3","key":"5683_CR66","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.revmed.2016.09.010","volume":"38","author":"M Catroux","year":"2017","unstructured":"Catroux\u00a0M, Lauda-Maillen\u00a0M, Pathe\u00a0M, De Boisgrollier de Ruolz\u00a0AC, Cazenave-Roblot\u00a0F, Roblot\u00a0P, Souchaud-Debouverie\u00a0O (2017) Infectious events during the course of autoimmune diseases treated with rituximab: A retrospective study of 93 cases. Rev Med Interne 38(3):160\u2013166. https:\/\/doi.org\/10.1016\/j.revmed.2016.09.010","journal-title":"Rev Med Interne"},{"issue":"9","key":"5683_CR67","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-021-01037-3","volume":"23","author":"CD Varley","year":"2021","unstructured":"Varley\u00a0CD, Winthrop\u00a0KL (2021) Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections). Curr Rheumatol Rep 23(9):74. https:\/\/doi.org\/10.1007\/s11926-021-01037-3","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"5683_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2025.102551","volume":"15","author":"V Yeap","year":"2025","unstructured":"Yeap\u00a0V, Liou\u00a0WL, Morvil\u00a0G, Kumar\u00a0R (2025) Real-world Prevalence of Hepatitis\u00a0B Reactivation in Patients With Resolved Hepatitis\u00a0B Receiving Rituximab and Non-rituximab-based Immunosuppressive Therapy Without Chemoprophylaxis. J\u00a0Clin Exp Hepatol 15(4):102551. https:\/\/doi.org\/10.1016\/j.jceh.2025.102551","journal-title":"J Clin Exp Hepatol"},{"key":"5683_CR69","unstructured":"(2025) Fachinformation MabThera\u00ae 100\u202fmg Konzentrat zur Herstellung einer Infusionsl\u00f6sung. https:\/\/www.fachinfo.de\/fi\/pdf\/002730. Accessed 15.1.2026"},{"issue":"5","key":"5683_CR70","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1610-0387.2007.06602.x","volume":"6","author":"M Hertl","year":"2008","unstructured":"Hertl\u00a0M, Zillikens\u00a0D, Borradori\u00a0L, Bruckner-Tuderman\u00a0L, Burckhard\u00a0H, Eming\u00a0R, Engert\u00a0A, Goebeler\u00a0M, Hofmann\u00a0S, Hunzelmann\u00a0N, Karlhofer\u00a0F, Kautz\u00a0O, Lippert\u00a0U, Niedermeier\u00a0A, Nitschke\u00a0M, Pf\u00fctze\u00a0M, Reiser\u00a0M, Rose\u00a0C, Schmidt\u00a0E, Shimanovich\u00a0I, Sticherling\u00a0M, Wolff-Franke\u00a0S (2008) Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J\u00a0Dtsch Dermatol Ges 6(5):366\u2013373. https:\/\/doi.org\/10.1111\/j.1610-0387.2007.06602.x","journal-title":"J Dtsch Dermatol Ges"},{"key":"5683_CR71","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.intimp.2017.11.005","volume":"54","author":"S Tavakolpour","year":"2018","unstructured":"Tavakolpour\u00a0S, Mahmoudi\u00a0H, Balighi\u00a0K, Abedini\u00a0R, Daneshpazhooh\u00a0M (2018) Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A\u00a0systematic review. Int Immunopharmacol 54:131\u2013138. https:\/\/doi.org\/10.1016\/j.intimp.2017.11.005","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"5683_CR72","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1080\/03009742.2017.1340514","volume":"47","author":"E Gazaix-Fontaine","year":"2018","unstructured":"Gazaix-Fontaine\u00a0E, Ottaviani\u00a0S, Dieud\u00e9\u00a0P (2018) Pleural tuberculosis under rituximab therapy for anti-synthetase syndrome. Scand J Rheumatol 47(4):338\u2013339. https:\/\/doi.org\/10.1080\/03009742.2017.1340514","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"5683_CR73","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1097\/MJT.0000000000001257","volume":"29","author":"R Sohal","year":"2020","unstructured":"Sohal\u00a0R, Sohal\u00a0S, Wazir\u00a0A, Lee\u00a0M (2020) Rituximab-Associated Reactivation of Tuberculosis. Am J Ther 29(1):e113\u2013e115. https:\/\/doi.org\/10.1097\/MJT.0000000000001257","journal-title":"Am J Ther"},{"issue":"12","key":"5683_CR74","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/rheumatology\/kew282","volume":"55","author":"P Fraticelli","year":"2016","unstructured":"Fraticelli\u00a0P, Bagnarelli\u00a0P, Tarantino\u00a0G, Martino\u00a0GP, Benfaremo\u00a0D, Nobili\u00a0L, Mandolesi\u00a0A, Barbisan\u00a0F, Marinelli\u00a0K, Mattioli\u00a0M, Murri\u00a0M, Gabrielli\u00a0A (2016) Chronic hepatitis\u00a0E in a\u00a0patient treated with rituximab and mycophenolate mofetil for Sj\u00f6gren\u2019s syndrome. Rheumatology (Oxford) 55(12):2275\u20132277. https:\/\/doi.org\/10.1093\/rheumatology\/kew282","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"5683_CR75","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jbspin.2015.11.010","volume":"83","author":"F Verhoeven","year":"2016","unstructured":"Verhoeven\u00a0F, Weil-Verhoeven\u00a0D, Di Martino\u00a0V, Prati\u00a0C, Thevenot\u00a0T, Wendling\u00a0D (2016) Management of acute HVE infection in a patient treated with rituximab for rheumatoid arthritis. Joint Bone Spine 83(5):577\u2013578. https:\/\/doi.org\/10.1016\/j.jbspin.2015.11.010","journal-title":"Joint Bone Spine"},{"issue":"1","key":"5683_CR76","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1365-3024.1993.tb00566.x","volume":"15","author":"DI Pritchard","year":"1993","unstructured":"Pritchard\u00a0DI (1993) Immunity to helminths: is too much IgE parasite--rather than host-protective? Parasite Immunol 15(1):5\u20139. https:\/\/doi.org\/10.1111\/j.1365-3024.1993.tb00566.x","journal-title":"Parasite Immunol"},{"issue":"2","key":"5683_CR77","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1365-2222.2007.02650.x","volume":"37","author":"AA Cruz","year":"2007","unstructured":"Cruz\u00a0AA, Lima\u00a0F, Sarinho\u00a0E, Ayre\u00a0G, Martin\u00a0C, Fox\u00a0H, Cooper\u00a0PJ (2007) Safety of anti-immunoglobulin\u00a0E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy 37(2):197\u2013207. https:\/\/doi.org\/10.1111\/j.1365-2222.2007.02650.x","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"5683_CR78","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1398-9995.2007.01601.x","volume":"63","author":"PJ Cooper","year":"2008","unstructured":"Cooper\u00a0PJ, Ayre\u00a0G, Martin\u00a0C, Rizzo\u00a0JA, Ponte\u00a0EV, Cruz\u00a0AA (2008) Geohelminth infections: a review of the role of IgE and assessment of potential risks of anti-IgE treatment. Allergy 63(4):409\u2013417. https:\/\/doi.org\/10.1111\/j.1398-9995.2007.01601.x","journal-title":"Allergy"},{"issue":"3","key":"5683_CR79","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/all.12818","volume":"71","author":"P Kolkhir","year":"2016","unstructured":"Kolkhir\u00a0P, Balakirski\u00a0G, Merk\u00a0HF, Olisova\u00a0O, Maurer\u00a0M (2016) Chronic spontaneous urticaria and internal parasites--a systematic review. Allergy 71(3):308\u2013322. https:\/\/doi.org\/10.1111\/all.12818","journal-title":"Allergy"},{"issue":"5","key":"5683_CR80","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3109\/17453674.2013.842431","volume":"84","author":"B E","year":"2013","unstructured":"E\u00a0B, P\u00a0G, A\u00a0G (2013) Continuation of TNF blockade in patients with inflammatory rheumatic disease. An observational study on surgical site infections in 1,596 elective orthopedic and hand surgery procedures. Acta Orthop 84(5):495\u2013501. https:\/\/doi.org\/10.3109\/17453674.2013.842431","journal-title":"Acta Orthop"},{"key":"5683_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2016.06.011","author":"C Mabille","year":"2017","unstructured":"Mabille\u00a0C, Degboe\u00a0Y, Constantin\u00a0A, Barnetche\u00a0T, Cantagrel\u00a0A, Ruyssen-Witrand\u00a0A (2017) Infectious risk associated to orthopaedic surgery for rheumatoid arthritis patients treated by anti-TNFalpha. Joint Bone Spine. https:\/\/doi.org\/10.1016\/j.jbspin.2016.06.011","journal-title":"Joint Bone Spine"},{"issue":"12","key":"5683_CR82","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.2106\/JBJS.21.00811","volume":"104","author":"BH van Duren","year":"2022","unstructured":"van Duren\u00a0BH, Wignall\u00a0A, Goodman\u00a0S, Hewitt\u00a0C, Mankia\u00a0K, Pandit\u00a0H (2022) The Effect of Perioperative Biologic Disease-Modifying Anti-Rheumatic Drugs on the Risk of Postoperative Complications: Surgical Site Infection, Delayed Wound Healing, and Disease Flares Following Orthopaedic Surgical Procedures. J\u00a0Bone Joint Surg Am 104(12):1116\u20131126. https:\/\/doi.org\/10.2106\/JBJS.21.00811","journal-title":"J Bone Joint Surg Am"},{"issue":"9","key":"5683_CR83","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1177\/2050640619878998","volume":"7","author":"Y Qiu","year":"2019","unstructured":"Qiu\u00a0Y, Zheng\u00a0Z, Liu\u00a0G, Zhao\u00a0X, He\u00a0A (2019) Effects of preoperative anti-tumour necrosis factor alpha infusion timing on postoperative surgical site infection in inflammatory bowel disease: A systematic review and meta-analysis. United European Gastroenterol\u00a0J 7(9):1198\u20131214. https:\/\/doi.org\/10.1177\/2050640619878998","journal-title":"United European Gastroenterol J"},{"issue":"1","key":"5683_CR84","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s00595-020-02003-9","volume":"51","author":"M Uchino","year":"2021","unstructured":"Uchino\u00a0M, Ikeuchi\u00a0H, Shimizu\u00a0J, Ohge\u00a0H, Haji\u00a0S, Mizuguchi\u00a0T, Mohri\u00a0Y, Yamashita\u00a0C, Kitagawa\u00a0Y, Suzuki\u00a0K, Kobayashi\u00a0M, Kobayashi\u00a0M, Sakamoto\u00a0F, Yoshida\u00a0M, Mayumi\u00a0T, Hirata\u00a0K, Takesue\u00a0Y (2021) Association between preoperative tumor necrosis factor alpha inhibitor and surgical site infection after surgery for inflammatory bowel disease: a\u00a0systematic review and meta-analysis. Surg Today 51(1):32\u201343. https:\/\/doi.org\/10.1007\/s00595-020-02003-9","journal-title":"Surg Today"},{"issue":"9","key":"5683_CR85","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/ddg.14947_g","volume":"21","author":"CR L\u00f6ser","year":"2023","unstructured":"L\u00f6ser\u00a0CR, Becker\u00a0SL, Hartmann\u00a0D, Kofler\u00a0L, Kunte\u00a0C, M\u00fcller\u00a0CSL, Schlager\u00a0JG, Balakirski\u00a0G (2023) Perioperative Antibiotikaprophylaxe in der Dermatochirurgie - Positionspapier der Arbeitsgruppe Antibiotic Stewardship der Deutschen Gesellschaft f\u00fcr Dermatochirurgie (DGDC), Teil 1: Eingriffs- und patientenbezogene Risikofaktoren. J\u00a0Dtsch Dermatol Ges 21(9):949\u2013957. https:\/\/doi.org\/10.1111\/ddg.14947_g","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05683-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-026-05683-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05683-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T12:25:40Z","timestamp":1779798340000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-026-05683-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":85,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5683"],"URL":"https:\/\/doi.org\/10.1007\/s00105-026-05683-5","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"26 March 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"G.\u00a0Balakirski\n                      : A.\u00a0Finanzielle Interessen: Vortrags- und Beraterhonorare sowie Honorare f\u00fcr Durchf\u00fchrung klinischer Studien von  AbbVie, Almirall, Amgen, AOP Health, AstraZeneca, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Janssen-Cilag, Leo Pharma, Novartis, Pfizer, Sanofi, and UCB Pharma. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Ober\u00e4rztin im Zentrum f\u00fcr Dermatologie, Allergologie und Dermatochirurgie, Helios Universit\u00e4tsklinikum Wuppertal, Universit\u00e4t Witten\/Herdecke, Wuppertal | Mitgliedschaften bei folgenden Fachgruppen: DDG, DGDC, EADV, EAACI, DGAKI, IDDG, ADI-TD.\n                      P.\u00a0Nenoff\n                      : A.\u00a0Finanzielle Interessen: Vortragshonorare von AbbVie, Almirall Hermal, bioM\u00e9rieux, Beiersdorf, Galderma, Janssen, MSD, Novartis, Dr.\u00a0Pfleger, Pfizer, Sanofi Genzyme, and UCB Pharma.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Niedergelassener Laborarzt in eigener Praxis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autorinnen und Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}